• $5.99

Publisher Description

XOMA Ltd. (Nasdaq:XOMA), Berkeley, Calif., a leader in the discovery and development of therapeutic antibodies, has announced its financial results for the third quarter ended September 30, 2010 and provided a general business update. "The next several months will see pivotal events in the development of our flagship anti-inflammatory antibody candidate, XOMA 052, for Type 2 diabetes," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "We expect to announce interim results from three months of treatment in our 74 patient Phase 2a clinical trial in early January. During the first quarter of 2011, we plan to release top line results from our 420 patient Phase 2b trial, which is designed to evaluate the activity of XOMA 052 in diabetes patients over six months of treatment. Positive results could bring a potentially disease-modifying therapeutic for the treatment of Type 2 diabetes a major step closer to patients."

GENRE
Business & Personal Finance
RELEASED
2010
December 1
LANGUAGE
EN
English
LENGTH
6
Pages
PUBLISHER
Worldwide Videotex
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
62.5
KB

More Books by Biotech Financial Reports